“This isn't simply a cancer story. It's an equity story,” said Meredith Cummins, CEO of NeuroEndocrine Cancer Australia. “Where you live, how far you are from specialist care, and your socioeconomic circumstances are increasingly influencing outcomes for people diagnosed with neuroendocrine cancer.” …
Widening inequality threatens outcomes for Australians with neuroendocrine cancer
July 14, 2026 Latest News
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News